NeuroInvestment announced the release of its May issue, which reviews novel treatments being developed for depression. Even though depression can be argued to be the success story of psychopharmacology, the current array of largely similar monoamine-targeting drugs leave 30% of patients without adequate relief, and incur significantly aversive side effects for the majority.
Popularity: unranked [?]
Related posts:
- Newer Class Of Antidepressants Similar In Effectiveness, Side Effects Differ
- New Treatments In Pipeline And Balanced Treatment For Depression The Future, Says ABPI Report
- Alternative Treatments For Depression: Transcranial Magnetic Stimulation (TMS) May Improve Mood, But Awaits FDA Approval
- Work With Tiny Worm Could Point To New Treatments For Human Brain Disorders
- Efficacy Similar Among Antidepressants, Side Effects Drive Multiple Prescriptions
Comments
No Responses to “Depression Treatments Reviewed By NeuroInvestment”